# Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

> **NCT05768919** · PHASE1,PHASE2 · RECRUITING · sponsor: **SignPath Pharma, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Treatment Period 1
- **DRUG:** Treatment Period 2
- **DRUG:** Treatment Period 3
- **DRUG:** Treatment Period 4a

## Key facts

- **NCT ID:** NCT05768919
- **Lead sponsor:** SignPath Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-03
- **Primary completion:** 2026-02
- **Final completion:** 2027-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05768919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05768919, "Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05768919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*